![Terrance P. Snutch](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Terrance P. Snutch
Corporate Officer/Principal presso University of British Columbia
Posizioni attive di Terrance P. Snutch
Società | Posizione | Inizio | Fine |
---|---|---|---|
University of British Columbia | Corporate Officer/Principal | - | - |
Storia della carriera di Terrance P. Snutch
Precedenti posizioni note di Terrance P. Snutch
Società | Posizione | Inizio | Fine |
---|---|---|---|
CombinatoRx, Inc.
![]() CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Direttore Tecnico/Scientifico/R&S | 22/12/2009 | 10/09/2010 |
Neuromed Pharmaceuticals Ltd.
![]() Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC. | Direttore Tecnico/Scientifico/R&S | 01/01/1998 | 27/01/2010 |
Fondatore | 28/12/2009 | 27/01/2010 | |
Neuromed Pharmaceuticals, Inc.
![]() Neuromed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals, Inc. develops new and improved pain medicines. It has multiple programs aimed at addressing this important unmet medical need. Its lead product candidate, ExalgoTM is an extended release formulation of hydromorphone in phase 3 clinical development. Neuromed is also developing oral drug candidates to block N-type and T-type calcium channels, an important target directly involved in pain signaling, and includes candidates for potentially treating pain, epilepsy and hypertension. | Direttore Tecnico/Scientifico/R&S | - | 27/01/2010 |
Formazione di Terrance P. Snutch
Simon Fraser University | Doctorate Degree |
Statistiche
Distribuzione geografica
Canada | 4 |
Stati Uniti | 3 |
Posizioni
Chief Tech/Sci/R&D Officer | 3 |
Founder | 1 |
Doctorate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 3 |
---|---|
Neuromed Pharmaceuticals Ltd.
![]() Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC. | Health Technology |
Neuromed Pharmaceuticals, Inc.
![]() Neuromed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals, Inc. develops new and improved pain medicines. It has multiple programs aimed at addressing this important unmet medical need. Its lead product candidate, ExalgoTM is an extended release formulation of hydromorphone in phase 3 clinical development. Neuromed is also developing oral drug candidates to block N-type and T-type calcium channels, an important target directly involved in pain signaling, and includes candidates for potentially treating pain, epilepsy and hypertension. | Health Technology |
CombinatoRx, Inc.
![]() CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Health Technology |
- Borsa valori
- Insiders
- Terrance P. Snutch
- Esperienza